BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34993612)

  • 21. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
    Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
    Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
    Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
    PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of the nuclear factor-kappa B (p65) in association with local failure in patients with head and neck carcinoma undergong radiotherapy or chemoradiotherapy.
    Quintana A; Avilés FX; Terra X; Alcolea S; Camacho M; Quer M; Vila L; León X
    Head Neck; 2013 Mar; 35(3):370-5. PubMed ID: 22422610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
    Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
    Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
    Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
    Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients.
    Sansa A; Venegas MDP; Valero C; Pardo L; Avilés-Jurado FX; Terra X; Quer M; León X
    Head Neck; 2021 Jul; 43(7):2091-2100. PubMed ID: 33675096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
    Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.
    Cheng H; Huang C; Xu X; Hu X; Gong S; Tang G; Song X; Zhang W; Wang J; Chen L; Yang J
    J Transl Med; 2017 Aug; 15(1):179. PubMed ID: 28851457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of CD45 transcriptional expression in head and neck cancer.
    Camacho M; Agüero A; Sumarroca A; López L; Pavón MÁ; Avilés-Jurado FX; García J; Quer M; León X
    Eur Arch Otorhinolaryngol; 2018 Jan; 275(1):225-232. PubMed ID: 29177949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
    Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
    JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD98 expression can be a predictive factor of resistance to radiotherapy in head and neck squamous cell carcinoma.
    Suzuki H; Kawasaki Y; Suzuki S; Yamada T; Ito A; Suzuki M; Miura M; Hatakeyama H; Omori Y
    Pol J Pathol; 2023; 74(2):122-130. PubMed ID: 37728471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known.
    Peltenburg B; Driessen JP; Vasmel JE; Pameijer FA; Janssen LM; Terhaard CHJ; de Bree R; Philippens MEP
    Eur Radiol; 2020 Feb; 30(2):1228-1231. PubMed ID: 31529258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
    Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
    Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28.
    Toth RK; Solomon R; Warfel NA
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
    Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
    J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy.
    Virós D; Camacho M; Zarraonandia I; García J; Quer M; Vila L; León X
    Oral Oncol; 2013 Apr; 49(4):322-5. PubMed ID: 23122824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.
    Zhang RX; Zhou ZG; Lu SX; Lu ZH; Wan DS; Pan ZZ; Wu XJ; Chen G
    Sci Rep; 2017 Nov; 7(1):16043. PubMed ID: 29167471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.